SIU Academy®. Faculty / Presenter(s) . 11/07/20; 312684 Topic: Kidney cancer
 Faculty / Presenter(s)
Faculty / Presenter(s)
About this activity
The treatment landscape for RCC is in an era of rapid progression with multiple exciting trials and ongoing pre-clinical studies. These promising new emerging therapies will likely continue to improve outcomes in patients with RCC. With these advances, there is an urgent need in the urological community to stay up-to-date with current guidelines and apply this knowledge to improve the outcomes for patients with RCC.


Thomas Powles, MBBS, MRCP, MD
Director, Barts Cancer Centre
Cancer Research UK 

Brian Rini, MD, FASCO
Vanderbilt University Medical Center
Nashville, TN

Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Toronto, Ontario, CANADA

This educational activity is made possible through the financial support of Merck Canada Inc. The opinions expressed are those of its authors and do not necessarly refleft the views and opinions of Merck Canada Inc. 


By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies